IQVIA (NYSE:IQV) Posts Earnings Results, Beats Expectations By $0.08 EPS

Posted by Brenda Bartman on Oct 27th, 2026

IQVIA (NYSE:IQV – Get Free Report) posted its quarterly earnings results on Tuesday. The medical research company reported $3.34 EPS for the quarter, topping analysts’ consensus estimates of $3.26 by $0.08, FiscalAI reports. The firm had revenue of $4.43 billion for the quarter, compared to analysts’ expectations of $4.37 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%.

IQVIA Stock Performance

Shares of IQVIA stock opened at $273.80 on Tuesday. The firm has a market cap of $45.07 billion, a P/E ratio of 33.97, a P/E/G ratio of 2.46 and a beta of 1.17. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA has a 12 month low of $154.50 and a 12 month high of $282.98. The stock’s fifty day moving average price is $263.36 and its 200-day moving average price is $209.63.

Insider Transactions at IQVIA

In related news, insider Eric Sherbet sold 5,000 shares of the company’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the completion of the sale, the insider directly owned 20,999 shares of the company’s stock, valued at $5,232,110.84. This represents a 19.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider W. Richard Staub sold 5,500 shares of the stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the transaction, the insider owned 13,312 shares in the company, valued at approximately $3,097,436.16. The trade was a 29.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 15,581 shares of company stock valued at $3,796,021 over the last three months. 1.70% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

IQV has been the subject of several research reports. HSBC boosted their price objective on shares of IQVIA from $280.00 to $300.00 and gave the company a “buy” rating in a research report on Tuesday, September 1st. Royal Bank Of Canada upped their target price on shares of IQVIA from $247.00 to $319.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 29th. TD Cowen raised their target price on shares of IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Morgan Stanley lifted their price target on shares of IQVIA from $240.00 to $270.00 and gave the company an “equal weight” rating in a research note on Thursday, September 17th. Finally, Truist Financial reiterated a “buy” rating and issued a $329.00 price target (up from $300.00) on shares of IQVIA in a report on Monday, September 28th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and a consensus price target of $278.75.

Check Out Our Latest Research Report on IQV

IQVIA Company Profile

(Get Free Report)

IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.

Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.